Massachusetts Financial Services Co. MA Grows Position in Ascendis Pharma A/S (NASDAQ:ASND)

Massachusetts Financial Services Co. MA grew its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 9.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,866,986 shares of the biotechnology company’s stock after buying an additional 155,971 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Ascendis Pharma A/S were worth $278,760,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD lifted its stake in shares of Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after buying an additional 336,976 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Ascendis Pharma A/S by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock worth $1,664,000 after acquiring an additional 4,338 shares during the period. Evolutionary Tree Capital Management LLC grew its position in shares of Ascendis Pharma A/S by 82.3% during the second quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company’s stock worth $3,391,000 after purchasing an additional 11,223 shares in the last quarter. SG Americas Securities LLC raised its stake in Ascendis Pharma A/S by 221.0% during the 2nd quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company’s stock valued at $833,000 after purchasing an additional 4,205 shares during the period. Finally, First Turn Management LLC lifted its holdings in Ascendis Pharma A/S by 23.1% in the 2nd quarter. First Turn Management LLC now owns 186,581 shares of the biotechnology company’s stock worth $25,446,000 after purchasing an additional 34,994 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $129.81 on Friday. The company has a market cap of $7.87 billion, a P/E ratio of -16.07 and a beta of 0.66. The business’s 50 day moving average price is $133.22 and its 200-day moving average price is $132.23. Ascendis Pharma A/S has a fifty-two week low of $90.13 and a fifty-two week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. As a group, equities analysts predict that Ascendis Pharma A/S will post -7.45 EPS for the current year.

Analysts Set New Price Targets

ASND has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $170.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Jefferies Financial Group lifted their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a report on Tuesday, August 13th. Bank of America increased their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Citigroup lifted their target price on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Finally, Evercore ISI increased their price target on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research note on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.